NeuroBloc
botulinum toxin type B
Table of contents
Overview
The marketing authorisation for NeuroBloc has been withdrawn at the request of the marketing-authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
NeuroBloc
|
| Agency product number |
EMEA/H/C/000301
|
| Active substance |
botulinum toxin type B
|
| International non-proprietary name (INN) or common name |
botulinum toxin type B
|
| Therapeutic area (MeSH) |
Torticollis
|
| Anatomical therapeutic chemical (ATC) code |
M03AX01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Sloan Pharma S.a.r.l
|
| Revision |
33
|
| Date of issue of marketing authorisation valid throughout the European Union |
22/01/2001
|
| Contact address |
33 Rue du Puits Romain |
Product information
04/03/2021 NeuroBloc - EMEA/H/C/000301 - IAIN/0107
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
NeuroBloc is indicated for the treatment of cervical dystonia (torticollis).
See section 5.1 for data on efficacy in patients responsive / resistant to botulinum toxin type A.